Risk factors for non-motor symptoms in Parkinson's disease

被引:263
作者
Marinus, Johan [1 ]
Zhu, Kangdi [1 ]
Marras, Connie [2 ,3 ]
Aarsland, Dag [4 ,5 ]
van Hilten, Jacobus J. [1 ]
机构
[1] Leiden Univ, Med Ctr, Dept Neurol, NL-2333ZA Leiden, Netherlands
[2] Univ Toronto, Morton & Gloria Shulman Movement Disorders Ctr, Toronto, ON, Canada
[3] Univ Toronto, Edmond J Safra Program Parkinsons Res, Univ Hlth Network, Toronto, ON, Canada
[4] Kings Coll London, Dept Old Age Psychiat, Inst Psychiat Psychol & Neurosci, London, England
[5] Stavanger Univ, Ctr Age Related Med, Stavanger, Norway
关键词
IMPULSE CONTROL DISORDERS; QUALITY-OF-LIFE; MILD COGNITIVE IMPAIRMENT; EXCESSIVE DAYTIME SLEEPINESS; PSYCHIATRIC-SYMPTOMS; FOLLOW-UP; VISUAL HALLUCINATIONS; DIAGNOSTIC-CRITERIA; DEMENTIA; DEPRESSION;
D O I
10.1016/S1474-4422(18)30127-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Non-motor symptoms (NMS) of Parkinson's disease can be predominant as the disease advances, thereby constituting a major source of disease burden for patients and caregivers. However, current understanding of NMS is incomplete, particularly as a result of the absence of standardisation of outcome definitions and the heterogeneity of the risk factors that are assessed. The best data on risk factors for NMS in Parkinson's disease come from longitudinal studies, with the strongest evidence identifying factors for cognitive impairment and dementia, hallucinations, depression, apathy, excessive daytime sleepiness, insomnia, and impulse-control disorders. Cognitive impairment, hallucinations, and depression have several common risk factors, and many other NMS share a few risk factors, showing the interdependence between NMS with advancing Parkinson's disease. Disease severity, sex, age, and antiparkinsonian medication might have roles in the development of different NMS, although only antiparkinsonian medication is potentially modifiable. Until disease-modifying therapies are developed, increased knowledge of risk factors could ameliorate early identification of patients who are at an increased risk of developing specific NMS and potentially allow improvement of symptom management or prevention of specific NMS.
引用
收藏
页码:559 / 568
页数:10
相关论文
共 93 条
  • [21] Cognitive impairment in patients with Parkinson's disease: A 30-month follow-up study
    Chen, Ling
    Yu, Cuiyu
    Zhang, Ning
    Liu, Junjun
    Liu, Weiguo
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2016, 151 : 65 - 69
  • [22] Parkinson's disease beyond 20 years
    Cilia, Roberto
    Cereda, Emanuele
    Klersy, Catherine
    Canesi, Margherita
    Zecchinelli, Anna L.
    Mariani, Claudio B.
    Tesei, Silvana
    Sacilotto, Giorgio
    Meucci, Nicoletta
    Zini, Michela
    Ruffmann, Claudio
    Isaias, Ioannis U.
    Goldwurm, Stefano
    Pezzoli, Gianni
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (08) : 849 - 855
  • [23] Apathy and cognitive and functional decline in community-dwelling older adults: results from the Baltimore ECA longitudinal study
    Clarke, Diana E.
    Ko, Jean Y.
    Lyketsos, Constantine
    Rebok, George W.
    Eaton, William W.
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2010, 22 (05) : 819 - 829
  • [24] Course of psychiatric symptoms and global cognition in early Parkinson disease
    de la Riva, Patricia
    Smith, Kara
    Xie, Sharon X.
    Weintraub, Daniel
    [J]. NEUROLOGY, 2014, 83 (12) : 1096 - 1103
  • [25] Review: Sporadic Parkinson's disease: development and distribution of -synuclein pathology
    Del Tredici, K.
    Braak, H.
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2016, 42 (01) : 33 - 50
  • [26] Apathy in Parkinson's disease: A systematic review and meta-analysis
    den Brok, Melina G. H. E.
    van Dalen, Jan Willem
    van Gool, Willem A.
    van Charante, Eric P. Moll
    de Bie, Rob M. A.
    Richard, Edo
    [J]. MOVEMENT DISORDERS, 2015, 30 (06) : 759 - 769
  • [27] Diagnostic procedures for Parkinson's disease dementia: Recommendations from the Movement Disorder Society Task Force
    Dubois, Bruno
    Burn, David
    Goetz, Christopher
    Aarsland, Dag
    Brown, Richard G.
    Broe, Gerald A.
    Dickson, Dennis
    Duyckaerts, Charles
    Cummings, Jefferey
    Gauthier, Serge
    Korczyn, Amos
    Lees, Andrew
    Levy, Richard
    Litvan, Irene
    Mizuno, Yoshikuni
    McKeith, Ian G.
    Olanow, C. Warren
    Poewe, Werner
    Sampaio, Cristina
    Tolosa, Eduardo
    Emre, Murat
    [J]. MOVEMENT DISORDERS, 2007, 22 (16) : 2314 - 2324
  • [28] The Changing Face of Parkinson's Disease-Associated Psychosis: A Cross-Sectional Study Based on the New NINDS-NIMH Criteria
    Fenelon, Gilles
    Soulas, Thierry
    Zenasni, Franck
    de Langavant, Laurent Cleret
    [J]. MOVEMENT DISORDERS, 2010, 25 (06) : 763 - 766
  • [29] Scales to assess psychosis in Parkinson's disease:: Critique and recommendations
    Fernandez, Hubert H.
    Aarsland, Dag
    Fenelon, Gilles
    Friedman, Joseph H.
    Marsh, Laura
    Troster, Alexander I.
    Poewe, Werner
    Rascol, Olivier
    Sampalo, Cristina
    Stebbins, Glenn T.
    Goetz, Christopher G.
    [J]. MOVEMENT DISORDERS, 2008, 23 (04) : 484 - 500
  • [30] Forsaa EB, 2010, ARCH NEUROL-CHICAGO, V67, P996, DOI 10.1001/archneurol.2010.166